Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery

Qian Ding; Zugui Zhang; Hong Liu; Huang Nie; Mark Berguson; Jordan E. Goldhammer; Nilas Young; Walter D Boyd; Rohinton Morris; Jianzhong Sun

doi:10.1038/s41467-019-11678-9

Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery

Qian Ding, Zugui Zhang, Hong Liu, Huang Nie, Mark Berguson, Jordan E. Goldhammer, Nilas Young, Walter D Boyd, Rohinton Morris, Jianzhong Sun

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

It remains disputable about perioperative use of renin-angiotensin system inhibitors (RASi) and their outcome effects. This multicenter retrospective cohort study examines association between use of perioperative RASi and outcomes in patients undergoing coronary artery bypass graft and/or valve surgery. After the exclusion, the patients are divided into 2 groups with or without preoperative RASi (PreRASi, n = 8581), or 2 groups with or without postoperative RASi (PostRASi, n = 8130). With using of propensity scores matching to reduce treatment selection bias, the study shows that PreRASi is associated with a significant reduction in postoperative 30-day mortality compared with without one (3.41% vs. 5.02%); PostRASi is associated with reduced long-term mortality rate compared with without one (6.62% vs. 7.70% at 2-year; 17.09% vs. 19.95% at 6-year). The results suggest that perioperative use of RASi has a significant benefit for the postoperative and long-term survival among patients undergoing cardiac surgery.

Original language	English (US)
Number of pages	1
Journal	Nature communications
Volume	10
Issue number	1
DOIs	https://doi.org/10.1038/s41467-019-11678-9
State	Published - Sep 13 2019

ASJC Scopus subject areas

Chemistry(all)
Biochemistry, Genetics and Molecular Biology(all)
Physics and Astronomy(all)

Access to Document

10.1038/s41467-019-11678-9

Cite this

Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery. / Ding, Qian; Zhang, Zugui; Liu, Hong; Nie, Huang; Berguson, Mark; Goldhammer, Jordan E.; Young, Nilas; Boyd, Walter D; Morris, Rohinton; Sun, Jianzhong.

In: Nature communications, Vol. 10, No. 1, 13.09.2019.

Research output: Contribution to journal › Article › peer-review

@article{9c2a54f5bb3c40378f02d49c2d4f8472,

title = "Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery",

abstract = "It remains disputable about perioperative use of renin-angiotensin system inhibitors (RASi) and their outcome effects. This multicenter retrospective cohort study examines association between use of perioperative RASi and outcomes in patients undergoing coronary artery bypass graft and/or valve surgery. After the exclusion, the patients are divided into 2 groups with or without preoperative RASi (PreRASi, n = 8581), or 2 groups with or without postoperative RASi (PostRASi, n = 8130). With using of propensity scores matching to reduce treatment selection bias, the study shows that PreRASi is associated with a significant reduction in postoperative 30-day mortality compared with without one (3.41% vs. 5.02%); PostRASi is associated with reduced long-term mortality rate compared with without one (6.62% vs. 7.70% at 2-year; 17.09% vs. 19.95% at 6-year). The results suggest that perioperative use of RASi has a significant benefit for the postoperative and long-term survival among patients undergoing cardiac surgery.",

author = "Qian Ding and Zugui Zhang and Hong Liu and Huang Nie and Mark Berguson and Goldhammer, {Jordan E.} and Nilas Young and Boyd, {Walter D} and Rohinton Morris and Jianzhong Sun",

year = "2019",

month = sep,

day = "13",

doi = "10.1038/s41467-019-11678-9",

language = "English (US)",

volume = "10",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery

AU - Ding, Qian

AU - Zhang, Zugui

AU - Liu, Hong

AU - Nie, Huang

AU - Berguson, Mark

AU - Goldhammer, Jordan E.

AU - Young, Nilas

AU - Boyd, Walter D

AU - Morris, Rohinton

AU - Sun, Jianzhong

PY - 2019/9/13

Y1 - 2019/9/13

N2 - It remains disputable about perioperative use of renin-angiotensin system inhibitors (RASi) and their outcome effects. This multicenter retrospective cohort study examines association between use of perioperative RASi and outcomes in patients undergoing coronary artery bypass graft and/or valve surgery. After the exclusion, the patients are divided into 2 groups with or without preoperative RASi (PreRASi, n = 8581), or 2 groups with or without postoperative RASi (PostRASi, n = 8130). With using of propensity scores matching to reduce treatment selection bias, the study shows that PreRASi is associated with a significant reduction in postoperative 30-day mortality compared with without one (3.41% vs. 5.02%); PostRASi is associated with reduced long-term mortality rate compared with without one (6.62% vs. 7.70% at 2-year; 17.09% vs. 19.95% at 6-year). The results suggest that perioperative use of RASi has a significant benefit for the postoperative and long-term survival among patients undergoing cardiac surgery.

AB - It remains disputable about perioperative use of renin-angiotensin system inhibitors (RASi) and their outcome effects. This multicenter retrospective cohort study examines association between use of perioperative RASi and outcomes in patients undergoing coronary artery bypass graft and/or valve surgery. After the exclusion, the patients are divided into 2 groups with or without preoperative RASi (PreRASi, n = 8581), or 2 groups with or without postoperative RASi (PostRASi, n = 8130). With using of propensity scores matching to reduce treatment selection bias, the study shows that PreRASi is associated with a significant reduction in postoperative 30-day mortality compared with without one (3.41% vs. 5.02%); PostRASi is associated with reduced long-term mortality rate compared with without one (6.62% vs. 7.70% at 2-year; 17.09% vs. 19.95% at 6-year). The results suggest that perioperative use of RASi has a significant benefit for the postoperative and long-term survival among patients undergoing cardiac surgery.

UR - http://www.scopus.com/inward/record.url?scp=85072200441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072200441&partnerID=8YFLogxK

U2 - 10.1038/s41467-019-11678-9

DO - 10.1038/s41467-019-11678-9

M3 - Article

C2 - 31519895

AN - SCOPUS:85072200441

VL - 10

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

ER -

Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this